Genetic and morphologic features for melanoma classification

Pigment Cell and Melanoma Research

Volumn 23, Issue 6, 2010, Pages 763-770

  Broekaert, Sigrid M C ^a   Roy, Ritu ^a,b   Okamoto, Ichiro ^c   Van Den Oord, Joost ^d   Bauer, Jürgen ^e   Garbe, Claus ^e   Barnhill, Raymond L ^f   Busam, Klaus J ^g   Cochran, Alistair J ^h   Cook, Martin G ⁱ   Elder, David E ^j   McCarthy, Stanley W ^k   Mihm, Martin C ^l   Schadendorf, Dirk ^m   Scolyer, Richard A ^k   Spatz, Alan ⁿ   Bastian, Boris C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^l HARVARD UNIVERSITY   (United States)

^m UNIVERSITY OF DUISBURG ESSEN   (Germany)

ⁿ MCGILL UNIVERSITY   (Canada)

more..

Author keywords

BRAF; Classification; Histomorphology; Melanoma; Mutation

Indexed keywords

B RAF KINASE;

ADULT; ARTICLE; CANCER CLASSIFICATION; CLASSIFICATION ALGORITHM; CLINICAL FEATURE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORPHOLOGY; ONCOGENE N RAS; PROTO ONCOGENE; REPRODUCIBILITY; VALIDATION STUDY;

AGED; ALGORITHMS; COHORT STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; WORLD HEALTH ORGANIZATION;

EID: 78049305326     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00778.x     Document Type: Article

References (24)

1. Balch, C.M., Buzaid, A.C., Atkins, M.B. et al. (2000). A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88, 1484-1491.
2. Bastian, B.C., Kashani-Sabet, M., Hamm, H., Godfrey, T., Moore, II D.H., Bröcker, E.B., LeBoit, P.E., and Pinkel, D. (2000). Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 60, 1968-1973.
3. Bastian, B.C., Olshen, A., LeBoit, P.E., and Pinkel, D. (2003). Classification of melanocytic tumors by DNA copy number changes. Am. J. Pathol. 163, 1765-1770.
4. Breiman, L., Friedman, J., Stone, C.J., and Olshen, R.A. (1984). Classification and Regression Trees, 1st edn. (Boca Raton, FL: Chapman and Hall/CRC).
5. Clark, W.H., From, L., Bernardino, E.A., and Mihm, M.C. (1969). The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 29, 705-727.
6. Conger, A. (1980). Integration and generalisation of Kappas for multiple raters. Psychol. Bull., 88, 322-328.
7. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
8. Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
9. Davison, A.C., and Hinkley, D.V. (1997) Bootstrap Methods and Their Application, 1st edn. (Cambridge, UK: Cambridge University Press).
10. Emery, C.M., Vijayendran, K.G., Zipser, M.C. et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106, 20411-20416.
11. Flaherty, K.T., Puzanov, I., Kim, K.B., Ribas, A., McArthur, G.A., Sosman, J.A., O'Dwyer, P.J., Lee, R.J., Grippo, J.F., Nolop, K., and Chapman, P.B. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
12. Heenan, P.J. (2003). Nodular melanoma is not a distinct entity. Arch Dermatol. 139, 387; author reply 387-8.
13. Kannengiesser, C., Spatz, A., Michiels, S. et al. (2008). Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol. Oncol., 1, 425-430.
14. Liu, W., Kelly, J.W., Trivett, M., et al. (2007). Distinct clinical and pathological features are associated with the BRAF (T1799A(V600E)) mutation in primary melanoma. J. Invest. Dermatol. 127, 900-905.
15. Maldonado, J.L., Fridlyand, J., Patel, H., Jain, A.N., Busam, K., Kageshita, T., Ono, T., Albertson, D.G., Pinkel, D., and Bastian, B.C. (2003). Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst. 95, 1878-1890.
16. Mehta, C.R., and Patel, N.R. (1986). ALGORITHM 643: FEXACT: a FORTRAN subroutine for Fisher's exact test on unordered r×c contingency tables. ACM Trans. Math. Softw. 12, 154-161.
17. Omholt, K., Platz, A., Kanter, L., Ringborg, U., and Hansson, J. (2003). NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 9, 6483-6488.
18. R Development Core Team (2010). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL
19. Reed, R. (1976) Acral lentiginous melanoma. In New Concepts in Surgical Pathology of the Skin (New York: John Wiley & Sons, Inc.) pp. 89-90
20. Thomas, N.E., Kanetsky, P.A., Begg, C.B., Conway, K., and Berwick, M. (2010). Melanoma molecular subtypes: unifying and paradoxical results. J. Invest. Dermatol. 130, 12-14.
21. Thompson, J.F., Scolyer, R.A., and Kefford, R.F. (2009). Cutaneous melanoma in the era of molecular profiling. Lancet, 374, 362-365.
22. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'Brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature, 457, 599-602.
23. Viros, A., Fridlyand, J., Bauer, J., Lasithiotakis, K., Garbe, C., Pinkel, D., and Bastian, B.C. (2008). Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 5, e120.
24. Winnepenninckx, V., Lazar, V., Michiels, S. et al. (2006). Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl Cancer Inst. 98, 472-482.